Blanca Homet Moreno - Concepedia

Author

Blanca Homet Moreno

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

B Homet Moreno, B Moreno, B. Homet Moreno, B. Moreno, B.H. Moreno, Beda P. Terrazas Moreno, Blanca H. Moreno, Blanca Homet Moreno

169

Publications

15.3K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, Los Angeles Institut Gustave Roussy Memorial Sloan Kettering Cancer Center University of Washington

About

Blanca Homet Moreno is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.8K
2	Health Sciences	8	8	207
3	Pathology	8	8	223
4	Immunology	6	6	494
5	Cell Biology	1	1	313

Blanca Homet Moreno

Publications

10.5K

Citations

H-Index

Page 1

	Year	Citations
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, New England Journal of Medicine	2016	3.1K
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Cell Reports	2017	1.8K
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> <sup> <i>V600E</i> </sup> melanoma Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, Science Translational Medicine	2015	562
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Journal of Clinical Oncology	2019	386
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Nature Medicine MedicineMelanomaImmune Checkpoint InhibitorOncologyRadiation Oncology	2019	319
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Nature Medicine Tumor ImmunologyCancer ImmunosurveillanceSkin CancerMedicineMelanoma	2019	313
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Journal of Clinical Oncology	2020	283
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Journal of Clinical Oncology	2022	246

Page 1